皮肤黑色素瘤辅助治疗:新疗法的系统评价与网状Meta分析
该系统评价与网状Meta分析纳入6项随机研究共4244例患者,评估达拉非尼联合曲美替尼、维莫非尼、纳武利尤单抗、伊匹木单抗和帕博利珠单抗作为黑色素瘤辅助治疗的无复发生存期、总生存期和不良事件。结果显示纳武利尤单抗在无复发生存期方面成为最佳治疗的概率最高(75.1%),帕博利珠单抗和纳武利尤单抗与不良事件关联最低的概率最高(分别为83.1%和64.4%)。总生存期无法估计,最佳选择取决于患者具体情况。
要点
- 纳武利尤单抗在RFS方面成为最佳辅助治疗的概率最高(75.1%)。
- 帕博利珠单抗和纳武利尤单抗与任何及3-4级AE关联最低的概率最高(83.1%和64.4%)。
- 总生存期无法估计,最佳治疗选择需结合患者具体情况。
核心结论
- 所有新药在辅助治疗中均高度有效,最佳选择取决于患者具体情况。
研究设计与样本
- 贝叶斯网状Meta分析,检索PubMed、Embase、Cochrane图书馆和美国临床肿瘤学会数据库至2018年8月20日,最终纳入6项随机研究共4244例患者。
主要发现
- 纳武利尤单抗在RFS方面成为最佳治疗的概率最高(75.1%),依次为达拉非尼联合曲美替尼、帕博利珠单抗、伊匹木单抗和维莫非尼。
- 帕博利珠单抗和纳武利尤单抗与任何及3-4级AE关联最低的概率最高(分别为83.1%和64.4%)。
- 总生存期无法估计。
关键数值与推荐
- 纳武利尤单抗RFS最佳概率75.1%。
- 帕博利珠单抗与任何及3-4级AE关联最低概率83.1%。
- 纳武利尤单抗与任何及3-4级AE关联最低概率64.4%。
临床怎么用
- 对于皮肤黑色素瘤辅助治疗,纳武利尤单抗在RFS和安全性方面概率占优,但需结合患者具体情况选择。
局限性
- 总生存期无法估计。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
New drugs have been recently approved as adjuvant therapies for melanoma. In this Bayesian network meta-analysis, we aimed to assess the best therapeutic option in terms of recurrence-free survival (RFS), overall survival (OS) and adverse events (AEs). PubMed, Embase, Cochrane library and the American Society of Clinical Oncology databases were searched from inception until 20 August 2018. We estimated adjusted hazard ratios (HRs) for RFS and OS and relative odds ratios (ORs) for AEs and surface under the cumulative ranking (SUCRA) probabilities were calculated. A number of 872 records were identified, and six were finally included in the meta-analysis. A total of 4244 patients in six studies were randomized. The following therapies were considered in the selected studies: combined dabrafenib and trametinib, vemurafenib, nivolumab, ipilimumab and pembrolizumab. Nivolumab demonstrated the highest probability (75.1%) of being the best in term of RFS, followed by dabrafenib+trametinib, pembrolizumab, ipilimumab and vemurafenib; however, OS was not estimable. Concerning AEs, pembrolizumab and nivolumab showed the highest probability to be less associated with any and 3-4 grade AEs (83.1% and 64.4%, respectively). In conclusion, all new drugs are highly effective in adjuvant setting, and the best choice is dependent of patient's context.
引用
- Longo C, Pampena R, Lallas A, et al. Adjuvant therapy for cutaneous melanoma: a systematic review and network meta-analysis of new therapies. J Eur Acad Dermatol Venereol. 2020. PMID: 31721319. doi:10.1111/jdv.16074
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。